Home Page - Slider
Monogram is a world leader in HIV drug resistance assays and viral tropism assays to aid in patient management.
Monogram has applied its virology expertise to hepatitis C. We offer a range of assays to assist with optimizing the treatment of patients with HCV.
The HERmark® Breast Cancer Assay is the industry’s first fully quantitative HER2 protein test based on Monogram’s proprietary VeraTag® protein quantification platform.
Monogram provides biopharmaceutical partners with clinical, scientific, and logistical support for drug development projects in HIV, HCV, and oncology.
Mutational data to guide regimen switches in suppressed patients
To assess NS5A drug susceptibility in patients with Hepatitis C
Precise quantification of patient HER2 expression